Cardurion
Burlington, US · Founded 2017 · 74 employees on LinkedIn · 12 known investors
Find your way into Cardurion
444 people in our graph share verified history with the Cardurion team — schools, employers, funds. One of them is your warm intro.
David Schenkeinunlockedknows Michael Mendelsohn · together at Tufts Medical Center (overlapped)
knows the team · via Foghorn Therapeutics, Inc
×2knows the team · via Harvard Medical School; Brigham and Women's Hospital
knows the team · via Tufts Medical Center
×6knows the team · via Amherst College
knows the team · via Merck & Co
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
Founders & leadership
Cardurion was founded in 2017 by Michael E. Mendelsohn and Michael Mendelsohn, M.D..
ME
Michael E. MendelsohninFounder and Chief Strategy OfficerMichael E. Mendelsohn is a physician-scientist with over 25 years of academic cardiovascular research experience at Tufts Medical Center and Brigham and Women's Hospital, and served as Senior Vice President and Global Franchise Head of Cardiovascular Diseases at Merck & Co. from 2010–2013 before founding Cardurion Pharmaceuticals.
MM
Michael Mendelsohn, M.D.inFounderMichael Mendelsohn is a physician with training in cardiovascular and internal medicine who served as senior vice president overseeing cardiovascular drug development at Merck before founding Cardurion Pharmaceuticals. He spent over two decades as an academic cardiovascular researcher at Tufts Medical Center and Brigham and Women's Hospital in Boston.
Investors · 12
Bain Capital✓ verified
Delos CapitalCambridge
Digitalis VenturesNew York · $100K – $10M
New Enterprise Associates (NEA)Menlo Park · $200K – $40M
Ascenta Capitalreported · 2 sourcesWilmington
Bain Capital Life SciencesreportedBoston
Bain Capital Tech OpportunitiesreportedBoston
Fidelity InvestmentsreportedBoston
GV (Google Ventures)reportedMountain View · $250K – $50M
InvusreportedNew York
Millennium ManagementreportedNew York
Also in the syndicate · 1
Bain
Funding
SEC filings, press & company announcements$260M disclosed across 1 of 2 rounds · 2024
- $260MSeries BJul 2024 · 3 sources
Ascenta Capital (lead), Bain, Bain Capital Life Sciences, GV, NEA
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Cardurion do?
- Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
- Who founded Cardurion?
- Cardurion was founded by Michael E. Mendelsohn, Michael Mendelsohn, M.D. in 2017.
- Who are Cardurion's investors?
- Cardurion's investors include Bain Capital, Delos Capital, Digitalis Ventures, New Enterprise Associates (NEA), Ascenta Capital, Bain Capital Life Sciences, Bain Capital Tech Opportunities, Fidelity Investments and 3 more.
- How much funding has Cardurion raised?
- Cardurion has disclosed $260M raised across 1 of its 2 known rounds.
- Where is Cardurion headquartered?
- Cardurion is headquartered in Burlington, US.